JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Amgen Inc

Abrir

SetorSaúde

285.35 -0.93

Visão Geral

Variação de preço das ações

24h

Atual

Mín

282.33

Máximo

287.62

Indicadores-chave

By Trading Economics

Rendimento

1.1B

1.7B

Vendas

-937M

8.1B

P/E

Médio do Setor

27.031

34.393

EPS

4.9

Rendimento de Dividendos

3.08

Margem de lucro

21.23

Funcionários

28,000

EBITDA

-1.7B

1.2B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+13.57% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.08%

2.54%

Próximos Ganhos

29 de out. de 2025

Próxima data de dividendos

12 de set. de 2025

Próxima data de ex-dividendo

22 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

4.3B

162B

Abertura anterior

286.28

Fecho anterior

285.35

Sentimento de Notícias

By Acuity

32%

68%

84 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Amgen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de ago. de 2025, 20:51 UTC

Ganhos

Amgen Posts Higher 2Q Profit, Revenue On Sales Growth Among Products

23 de jun. de 2025, 19:24 UTC

Grandes Movimentos do Mercado

Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update

23 de jun. de 2025, 19:07 UTC

Grandes Movimentos do Mercado

Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial

1 de mai. de 2025, 20:17 UTC

Ganhos

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen Sees FY Rev $35B-$36B >AMGN

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen Sees FY EPS $10.97-EPS $12.11 >AMGN

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen Sees FY Adj EPS $20.20-Adj EPS $21.30 >AMGN

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen 2Q Worldwide Prolia Sales $1.12B >AMGN

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen 2Q Worldwide XGEVA Sales $532M >AMGN

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen 2Q Net $1.43B >AMGN

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen 2Q Worldwide Enbrel Sales $604M >AMGN

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen 2Q Worldwide Neulasta Sales $82M >AMGN

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen 2Q Rev $9.2B >AMGN

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen 2Q Adj EPS $6.02 >AMGN

5 de ago. de 2025, 20:01 UTC

Ganhos

Amgen 2Q EPS $2.65 >AMGN

28 de mai. de 2025, 18:09 UTC

Ganhos

Heart Disease Could Be a Goner When These New -2-

28 de mai. de 2025, 18:09 UTC

Ganhos

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

19 de mai. de 2025, 16:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen: FY25 Share Repurchases Not to Exceed $500M

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen Sees FY25 Capital Expenditures About $2.3B

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen 1Q Repatha Sales $656M >AMGN

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen 1Q EVENITY Sales $442M >AMGN

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen 1Q Net $1.73B >AMGN

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen 1Q Adj EPS $4.90 >AMGN

1 de mai. de 2025, 20:01 UTC

Ganhos

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

Comparação entre Pares

Variação de preço

Amgen Inc Previsão

Preço-alvo

By TipRanks

13.57% parte superior

Previsão para 12 meses

Média 327.35 USD  13.57%

Máximo 405 USD

Mínimo 272 USD

Com base em 22 analistas de Wall Street que oferecem metas de preço de 12 meses para Amgen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

22 ratings

11

Comprar

10

Manter

1

Vender

Pontuação Técnica

By Trading Central

270.44 / 276.44Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

84 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.